Glutamine-enriched enteral nutrition in very low birthweight infants and allergic and infectious diseases at 6 years of age.
In a previous randomised controlled trial, we found that glutamine-enriched enteral nutrition in 102 very low birthweight (VLBW) infants decreased both the incidence of serious infections in the neonatal period and the risk of atopic dermatitis during the first year of life. We hypothesised that glutamine-enriched enteral nutrition in VLBW infants in the neonatal period influences the risk of allergic and infectious disease at 6 years of age. Eighty-eight of the 102 infants were eligible for the follow-up study (13 died, 1 chromosomal abnormality). Doctor-diagnosed allergic and infectious diseases were assessed by means of validated questionnaires. The association between glutamine-enriched enteral nutrition in the neonatal period and allergic and infectious diseases at 6 years of age was based on univariable and multivariable logistic regression analyses. Seventy-six of the 89 (85%) infants participated, 38 in the original glutamine-supplemented group and 38 in the control group. After adjustment, we found a decreased risk of atopic dermatitis in the glutamine-supplemented group: adjusted odds ratio (aOR) 0.23 [95% CI 0.06, 0.95]. No association between glutamine supplementation and hay fever, recurrent wheeze and asthma was found. A decreased risk of gastrointestinal tract infections was found in the glutamine-supplemented group (aOR) 0.10 [95% CI 0.01, 0.93], but there was no association with upper respiratory, lower respiratory or urinary tract infections. We concluded that glutamine-enriched enteral nutrition in the neonatal period in VLBW infants decreased the risk of atopic dermatitis and gastrointestinal tract infections at 6 years of age.
Department of Pediatrics, VU University Medical Center, Amsterdam, The Netherlands.
Annelies
A
van Zwol
Henriëtte A
HA
Moll
Willem P F
WP
Fetter
Ruurd M
RM
van Elburg
D002648:Child; D003141:Communicable Diseases / Q000453:epidemiology* / Q000276:immunology; D003876:Dermatitis, Atopic / Q000453:epidemiology* / Q000276:immunology; D019587:Dietary Supplements; D004750:Enteral Nutrition / Q000379:methods*; D005500:Follow-Up Studies; D005767:Gastrointestinal Diseases / Q000453:epidemiology / Q000276:immunology; D005973:Glutamine / Q000008:administration & dosage*; D006801:Humans; D006967:Hypersensitivity / Q000453:epidemiology* / Q000276:immunology; D007231:Infant, Newborn; D019102:Infant, Very Low Birth Weight; D016032:Randomized Controlled Trials as Topic; D012044:Regression Analysis; D018570:Risk Assessment; D011795:Surveys and Questionnaires; D014570:Urologic Diseases / Q000453:epidemiology / Q000276:immunology
D005973:Glutamine